Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	109046
Country	Thailand

Category	Gastroenterology & Hepatology
Manuscript Type	Prospective Study
Article Title	Electroacupuncture alleviates symptoms and identifies a potential microbial biomarker in patients with constipation-predominant irritable bowel syndrome
Manuscript Source	Unsolicited Manuscript
All Author List	Kiangyada Yaklai, Chanon Kunasol, Kanokphong Suparan, Nattayaporn Apaijai, Taned Chitapanarux, Sintip Pattanakuhar, Nipon Chattipakorn and Siriporn C Chattipakorn
Funding Agency and Grant Number
Corresponding Author	Siriporn C Chattipakorn, DDS, PhD, Professor, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Muang 50200, Chiang Mai, Thailand. scchattipakorn@gmail.com
Key Words	Irritable bowel syndrome; Traditional Chinese Medicine; Gut microbiota; Constipation; Microbial biomarker
Core Tip	Given the complex pathophysiology of irritable bowel syndrome (IBS), inconsistency of gut microbiota profiles, and the scarce evidence regarding constipation subtype, current treatments often focus on symptom management. Electroacupuncture (EA), as an alternative or complementary approach, has shown clinical efficacy. Our study demonstrated that EA not only alleviated constipation-predominant type (IBS-C) symptoms but also modulated gut dysbiosis and normalized neurotransmitter-related metabolic pathways. Notably, Senegalimassilia was positively linked with clinical improvement, suggesting its potential as a predictive biomarker of EA responsiveness. Additionally, EA offered sustained beneficial therapeutic effects in IBS-C through gut microbiota modulation, supporting its role in clinical practice.
Citation	Yaklai K, Kunasol C, Suparan K, Apaijai N, Chitapanarux T, Pattanakuhar S, Chattipakorn N, Chattipakorn SC. Electroacupuncture alleviates symptoms and identifies a potential microbial biomarker in patients with constipation-predominant irritable bowel syndrome. World J Gastrointest Pharmacol Ther 2025; In press

Received	2025-04-29 04:35
Peer-Review Started	2025-04-29 04:35
To Make the First Decision
Return for Revision	2025-05-18 06:54
Revised	2025-05-23 13:47
Second Decision	2025-07-01 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-02 06:05
Articles in Press	2025-07-02 06:05
Publication Fee Transferred	2025-06-01 03:02
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com